<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="841">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05150210</url>
  </required_header>
  <id_info>
    <org_study_id>SP Thoracic IDE</org_study_id>
    <nct_id>NCT05150210</nct_id>
  </id_info>
  <brief_title>SP Thoracic IDE Study</brief_title>
  <official_title>A Prospective, Multi-Center Investigation of the da Vinci SP Surgical System in Pulmonary and Lobectomy for Benign and Malignant Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intuitive Surgical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intuitive Surgical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To confirm the safety and performance of the da Vinci SP Surgical System, Instruments and&#xD;
      Accessories in pulmonary lobectomy, and in thymectomy procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary performance:&#xD;
&#xD;
      The primary endpoint will be assessed as the ability to complete the planned da Vinci&#xD;
      SP-assisted thoracic procedure without conversion to an alternate approach. Conversion to an&#xD;
      alternate approach comprises undocking of the da Vinci SP to complete the planned procedures&#xD;
      using other methods, such as open, VATS, or multiport robotic (da Vinci SI or X/Xi)&#xD;
&#xD;
      Primary Safety:&#xD;
&#xD;
      The primary safety endpoint will be assessed as the incidence of all intra-operative and&#xD;
      post-operative adverse events that occur through the 30-day follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2022</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance</measure>
    <time_frame>Intra-operative period</time_frame>
    <description>Performance defined as the ability to complete the planned da Vinci SP-assisted pulmonary lobectomy and thymectomy procedures without conversion to an alternate approach</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Event Rates</measure>
    <time_frame>Intra-operative through the 30 days follow-up period</time_frame>
    <description>Safety defined as the incidence of all intra-operative and post-operative adverse events that occur through the 30-day follow-up period.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pulmonary Lobectomy and Thymectomy for Benign and Malignant Cases</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmonary lobectomy and thymectomy procedures will be performed by da Vinci SP Surgical System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Robotic-Assisted Surgery</intervention_name>
    <description>da Vinci SP Surgical System, instruments, and accessories in pulmonary lobectomy and thymectomy for benign and malignant disease.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 21 years&#xD;
&#xD;
          -  BMI ≤ 35&#xD;
&#xD;
          -  ASA ≤ 3&#xD;
&#xD;
          -  Willing and able to provide a written informed consent&#xD;
&#xD;
          -  Willing and able to comply with the study protocol requirements including follow-up&#xD;
             examinations at 14 days and 30 days post-operatively, and post-market long term&#xD;
             follow-up on an annual basis through 5 years&#xD;
&#xD;
        Lobectomy Inclusion Criteria:&#xD;
&#xD;
        - Clinical stage I or II primary lung cancer or other suspected lung malignancy; or benign&#xD;
        lung disease requiring resection; primary tumor ≤ 5cm diameter&#xD;
&#xD;
        Thymectomy Inclusion Criteria:&#xD;
&#xD;
        - Masaoka clinical stage I or II thymoma; or thymectomy for myasthenia gravis; thymic mass&#xD;
        ≤ 5 cm diameter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical or radiological evidence of mediastinal or systemic metastatic disease&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
&#xD;
          -  Subject with a known bleeding or clotting disorder&#xD;
&#xD;
          -  Subjects actively receiving therapeutic-dose anticoagulation or anti-platelet&#xD;
             medications at the time of operation&#xD;
&#xD;
          -  Uncontrolled systemic illness 6 months prior to planned surgical procedure including,&#xD;
             but not limited to ongoing or active infection, symptomatic congestive heart failure,&#xD;
             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations&#xD;
             that would limit compliance with study requirements&#xD;
&#xD;
          -  Previous chemotherapy, immunotherapy and/or radiation therapy for treatment of the&#xD;
             cancer to be resected&#xD;
&#xD;
          -  Subject has a contraindication for general anesthesia or surgery&#xD;
&#xD;
          -  Subjects under active immunomodulatory or immunosuppressive regimen (e.g. transplant&#xD;
             patient, high-dose steroid requirement) within 30 days prior to the planned surgical&#xD;
             procedure. For myasthenia patients, if steroids are weaned down to prednisone ≤ 5&#xD;
             mg/day prior to day of surgery, the patient may be enrolled&#xD;
&#xD;
          -  Previous sternotomy&#xD;
&#xD;
          -  Subject belongs to vulnerable population&#xD;
&#xD;
          -  Subject is pregnant or suspected to be pregnant or breastfeeding&#xD;
&#xD;
        Lobectomy Exclusion Criteria:&#xD;
&#xD;
          -  Tumor involving carina or any airway requiring sleeve resection, bronchoplasty&#xD;
&#xD;
          -  Tumor requiring resection of local structures (e.g. chest wall) or extended resection&#xD;
             such as bilobectomy&#xD;
&#xD;
          -  History of pulmonary hypertension&#xD;
&#xD;
          -  Previous ipsilateral thoracic surgery or radiotherapy&#xD;
&#xD;
        Thymectomy Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled myasthenia gravis symptoms at the time of scheduled surgery&#xD;
&#xD;
          -  Tumor requiring resection of local structures (except pericardium)&#xD;
&#xD;
          -  Confirmed thymic carcinoma&#xD;
&#xD;
        Intraoperative Exclusion Criteria:&#xD;
&#xD;
        - Anatomy determined intra-operatively to be unsuitable for minimally invasive surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Rice, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Mueller</last_name>
    <phone>510-552-9880</phone>
    <email>jennifer.mueller@intusurg.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Syvlie Akiel-Fu</last_name>
    <email>sylvie.akiel-fu@intusurg.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

